Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib vs Investigator's Choice in Relapsed/Refractory Peripheral T-cell Lymphoma
TCTR20250224006Phase 3Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started May 2024; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on TCTR20250224006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250224006.